

## Neuren to present at autism research meeting

**Melbourne, Australia:** Neuren Pharmaceuticals (ASX: NEU) today announced the acceptance of an abstract for presentation at the 2025 International Society for Autism Research (INSAR) Annual Meeting, being held 30 April - 3 May 2025, in Seattle Washington. Details of the presentation are as follows:

### “Many Apparent False Negatives in Detection of Mutations in Gene Associated with Autism Spectrum Disorders”

- Presentation Type: Poster
- Date: Thursday, 1 May

All INSAR Annual Meeting content to be presented or published is embargoed until the time of the actual presentation. Posters will be embargoed until Thursday, 1 May.

Neuren Vice President of Clinical Development Nancy Jones PhD commented: “The importance of accurate genetic testing for children with developmental delay cannot be overstated. We hope that in bringing to light the shortcomings in current genetic testing, methodologies will improve and more children and families can receive a diagnosis.”

### About Neuren

Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, all programs have been granted “orphan drug” designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.

DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) and Health Canada for the treatment of Rett syndrome. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide.

Neuren’s second drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome.

### Contact

*Investor relations*

[investorrelations@neurenpharma.com](mailto:investorrelations@neurenpharma.com)

Jon Pilcher, CEO: +61 438 422 271

*Scientific enquiries and medical enquiries*

[medicalinformation@neurenpharma.com](mailto:medicalinformation@neurenpharma.com)

**ASX Listing Rules information**

This announcement was authorized to be given to the ASX by the CEO & Managing Director of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124

**Forward-looking Statements**

*This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.*

For personal use only